$FENC
FENNEC PHARMACEUTICALS INC.

2018 Q4 Form 10-K Financial Statement

#000114420419014220 Filed on March 15, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2018 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.380M $5.400M $1.630M
YoY Change -15.34% 7.57% 68.04%
% of Gross Profit
Research & Development $1.720M $5.008M $890.0K
YoY Change 93.26% 158.68% 423.53%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.110M $5.008M $2.520M
YoY Change 23.41% 158.68% 119.13%
Operating Profit -$10.41M
YoY Change 49.75%
Interest Expense $120.0K $520.0K $230.0K
YoY Change -47.83% -677.78% 2200.0%
% of Operating Profit
Other Income/Expense, Net $10.00K $521.0K $0.00
YoY Change -648.42%
Pretax Income -$2.980M -$7.702M -$2.290M
YoY Change 30.13% 9.31% 100.88%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.980M -$9.888M -$2.290M
YoY Change 30.13% 40.33% 100.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$150.4K -$522.2K -$139.1K
COMMON SHARES
Basic Shares Outstanding 19.73M shares 18.94M
Diluted Shares Outstanding 18.94M

Balance Sheet

Concept 2018 Q4 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.78M $22.78M $28.26M
YoY Change -19.39% -19.39% 619.08%
Cash & Equivalents $22.78M $22.78M $28.26M
Short-Term Investments
Other Short-Term Assets $1.000K $170.0K $13.00K
YoY Change -92.31% 21.43% 333.33%
Inventory
Prepaid Expenses $168.0K $128.0K
Receivables
Other Receivables
Total Short-Term Assets $22.95M $22.95M $28.40M
YoY Change -19.19% -19.19% 615.39%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $22.95M $22.95M $28.40M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $22.95M $22.95M $28.40M
YoY Change -19.19% -19.19% 615.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.032M $1.030M $855.0K
YoY Change 20.7% 19.77% 250.41%
Accrued Expenses $605.0K $610.0K $622.0K
YoY Change -2.73% -1.61% 397.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.637M $1.640M $1.644M
YoY Change -0.43% 0.0% 308.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.637M $1.640M $1.644M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.637M $1.640M $1.644M
YoY Change -0.43% 0.0% 308.96%
SHAREHOLDERS EQUITY
Retained Earnings -$131.3M -$121.4M
YoY Change 8.15% 6.16%
Common Stock $151.3M $146.9M
YoY Change 3.03% 25.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.31M $21.31M $26.76M
YoY Change
Total Liabilities & Shareholders Equity $22.95M $22.95M $28.40M
YoY Change -19.19% -19.19% 615.03%

Cashflow Statement

Concept 2018 Q4 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$2.980M -$9.888M -$2.290M
YoY Change 30.13% 40.33% 100.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.930M -$7.826M -$1.320M
YoY Change 121.97% 114.94% 116.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.190M 2.347M 19.90M
YoY Change -94.02% -91.61%
NET CHANGE
Cash From Operating Activities -2.930M -7.826M -1.320M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 1.190M 2.347M 19.90M
Net Change In Cash -1.740M -5.479M 18.58M
YoY Change -109.36% -122.52% -3145.9%
FREE CASH FLOW
Cash From Operating Activities -$2.930M -$7.826M -$1.320M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Assets
Assets
22950000
CY2017Q4 us-gaap Assets
Assets
28401000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22781000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28260000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
168000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
128000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1032000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
855000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
605000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
622000
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
167000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1637000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1644000
CY2018Q4 us-gaap Liabilities
Liabilities
1637000
CY2017Q4 us-gaap Liabilities
Liabilities
1644000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
106392000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
103045000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
44934000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43837000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131256000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121368000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
21313000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
26757000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22950000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28401000
CY2018 us-gaap Revenues
Revenues
0
CY2017 us-gaap Revenues
Revenues
0
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5008000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1936000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5401000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5015000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-10409000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-6951000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
521000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-95000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18942000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15014000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-9888000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-7046000
CY2018 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
272000
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
741000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1825000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1517000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
177000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
611000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-17000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
497000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7826000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3641000
CY2018 fencf Proceeds From Short Swing Profit Judgment Offset With Settlement Expense
ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense
18000
CY2017 fencf Proceeds From Short Swing Profit Judgment Offset With Settlement Expense
ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense
0
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2347000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27975000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3926000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
3570000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
563000
CY2017 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
31000
CY2018 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
18000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
210000
CY2018Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
22800000
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
28300000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18942000
CY2018 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18942000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
22781000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19896000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18411000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19896000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18411000
CY2018Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
167000
CY2017 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-134000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2018 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
348000
CY2017 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
47000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2018 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
40000
CY2017 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
85000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-12000
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27381000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
210000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
563000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2119000
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
31000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5479000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24334000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27381000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period.&#160;Significant estimates include the valuation of derivative warrant liability and the valuation of stock-based compensation.&#160;Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15014000
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15014000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-7702000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5277000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2145000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1769000
CY2018 fencf Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
-9847000
CY2017 fencf Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
-7046000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650
CY2018 fencf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
-2609000
CY2017 fencf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
-1867000
CY2018 fencf Permanent Difference
PermanentDifference
512000
CY2017 fencf Permanent Difference
PermanentDifference
636000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2042000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
328000
CY2018 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0
CY2017 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
843000
CY2018 fencf Income Tax Reconciliation Tax Credits Other Adjustments
IncomeTaxReconciliationTaxCreditsOtherAdjustments
0
CY2017 fencf Income Tax Reconciliation Tax Credits Other Adjustments
IncomeTaxReconciliationTaxCreditsOtherAdjustments
-3000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
55000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
63000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26020000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23920000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
26020000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
23920000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
167000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8600000
CY2018Q4 us-gaap Cash
Cash
121000000
CY2016Q4 fencf Stock Options Issuance
StockOptionsIssuance
40000
CY2016Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
1.81
CY2017 fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
-21000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.90
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2017Q4 fencf Stock Options Issuance
StockOptionsIssuance
19000
CY2017Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
1.71
CY2018 fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
-19000
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.71
CY2018Q4 fencf Stock Options Issuance
StockOptionsIssuance
0
CY2018Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
0
CY2018Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1100000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2100000
CY2018 us-gaap Description Of Difference Between Reported Amount And Reporting Currency Denominated Amount
DescriptionOfDifferenceBetweenReportedAmountAndReportingCurrencyDenominatedAmount
exchange rate of $CAD/$USD 0.7715
CY2017Q3 fencf Number Of Common Shares Registered
NumberOfCommonSharesRegistered
11900000
CY2018Q4 us-gaap Registration Payment Arrangement Maximum Potential Consideration
RegistrationPaymentArrangementMaximumPotentialConsideration
68800000
CY2018Q4 fencf Proceeds From Registration Payment Arrangement
ProceedsFromRegistrationPaymentArrangement
21200000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4000000
CY2018 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
2119000
CY2018Q4 us-gaap Cash
Cash
770000000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
28260000
CY2018Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0
CY2017Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
167000
CY2017Q4 us-gaap Cash
Cash
275000000
CY2017Q4 us-gaap Cash
Cash
255000000
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001211583
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
82970261
CY2018 dei Trading Symbol
TradingSymbol
FENCF
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19895830
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-19-014220-index-headers.html Edgar Link pending
0001144204-19-014220-index.html Edgar Link pending
0001144204-19-014220.txt Edgar Link pending
0001144204-19-014220-xbrl.zip Edgar Link pending
ex21x1_001.jpg Edgar Link pending
fencf-20181231.xml Edgar Link completed
fencf-20181231.xsd Edgar Link pending
fencf-20181231_cal.xml Edgar Link unprocessable
fencf-20181231_def.xml Edgar Link unprocessable
fencf-20181231_lab.xml Edgar Link unprocessable
fencf-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv515201_10k.htm Edgar Link pending
tv515201_ex21-1.htm Edgar Link pending
tv515201_ex23-1.htm Edgar Link pending
tv515201_ex31-1.htm Edgar Link pending
tv515201_ex31-2.htm Edgar Link pending
tv515201_ex32-1.htm Edgar Link pending
tv515201_img01.jpg Edgar Link pending